Before you can access ASH's online program, you must agree to the following:
Abstracts submitted to the ASH Annual Meeting are
considered embargoed from the time of submission.
The media, companies and institutions issuing press releases,
and others are required to abide by the embargo policies governing
the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes and differs from the print
version in some details.
Lian Xu1*, Bryan Ciccarelli1*, Evdoxia Hatjiharissi, MD2, Guang Yang, PhD3*, Yangsheng Zhou, MD, PhD4*, Zachary Hunter1*, Jenny Sun, MD4*, Ping Gong5*, Xia Liu4*, Hsiuyi Tseng4*, Thea Ioakimidis, MS5*, Robert Manning4*, Christina Hanzis1*, Yang Cao5*, Megan Lewicki5*, Christopher J Patterson6* and Steven Treon, MD, PhD2
1Hematology-Oncology, Dana Farber Cancer Institute, Boston, MA 2Dana-Farber Cancer Institute, Boston, MA 3Medical Oncology, Dana-Farber Cancer Inst., Boston, MA 4Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 5Dana Farber Cancer Institute, Boston, MA 6Waldenstrom's macroglubulinemia center, Dana-Farber Cancer Institute, Boston, MA
Maria Monne1*, Giovanna Piras1*, Antonella Uras1*, Marco Murineddu1*, Angelo D. Palmas1, Giovanna Pira1*, Maria Antonietta Fancello1*, Gian Carlo Latte1*, Alessandro Murgia1*, Angelo Novelli2*, Salvatore Deledda2* and Attilio Gabbas1*
Florian Kuchenbauer, MD1, Sarah M Mah2*, Andrew McPherson3*, Michael Heuser, MD4, Bob Argiropolous, PhD2*, Ryan Morin, PhD5*, Tobias Berg, MD6, David Lai2*, Andrew L Muranyi, BSc7*, Donna E. Hogge, MD, PhD8, Jens Ruschmann, PhD7*, Daniel T. Starczynowski, PhD9, Aly Karsan, MD10, Michael O'Connor, PhD7*, Connie J. Eaves, PhD11, Akira Watahiki, MD, PhD10*, Yuzhuo Wang, PhD10*, Samuel Aparicio, PhD10*, Arnold Ganser, MD, PhD12, Juergen Krauter, MD12*, Jonathan Johnnidis, PhD13*, Marco Marra, PhD14, Fernando Carmago, PhD13* and R. Keith Humphries, MD, PhD11
1Institut für Experimentelle Tumorforschung, Universität Ulm, Ulm, Germany 2Terry Fox Lab, BCCRC, Vancouver, BC, Canada 3BC Genome Science Centre, Vancouver, BC, Canada 4MH Hannover, Hannover, Germany 5Genome Sciences Centre, BC Cancer Research Centre, Vancouver, BC, Canada 6Terry Fox Laboratories, Vancouver, BC, Canada 7Terry Fox Laboratory, B.C. Cancer Agency, Vancouver, BC, Canada 8Division of Hematology and Leukemia/BMT, University of British Columbia, Vancouver, BC, Canada 9Dept. of Medical Biophysics, BC Cancer Research Ctr., Vancouver, BC, Canada 10British Columbia Cancer Rsch. Ctr., Vancouver, BC, Canada 11Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada 12Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany 13Whitehead Institute for Biomedical Research, Cambridge, MA 14Genome Sciences Center, British Columbia Cancer Agency, Vancouver, BC, Canada
1Department of Molecular Oncology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan 2Department of Developmental Biology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan
Jillian F Wise, BS1*, Zuzana Berkova, Ph.D.2*, Urszula Daniluk1*, Ronghua Tao, M.D., Ph.D.2*, Steven Ovu3*, Om Prakash4* and Felipe Samaniego, MD5
1Lymphoma/Myeloma, M.D. Anderson Cancer Center, Houston, TX 2Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX 3Lymphoma, MD Anderson Cancer Center, Houston, TX 4Ochsner Clinic Foundation, New Orleans, LA 5Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
Enas R Yassin, MD1*, Anmaar M Abdul-Nabi, MD2*, Akiko Takeda, PhD3 and Nabeel R. Yaseen, MD, PhD4
1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO 2Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 3Washington University Sch of Medicine, Saint Louis, MO 4Washington University in St Louis, Saint Louis, MO
Evelena Ontiveros1, David Dae-Young Kim1, Jeffrey M Calimlim1*, Matthew I. Schrage2*, Quang T Luong1*, Debra Tosity2*, Bao Ngan Doan2*, Brandon Castor2*, Michael A. Teitell2*, Jonathan W Said2* and Sven De Vos1
1Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA 2Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
1Cancer Genomics Project, University of Tokyo, Tokyo, Japan 2Division of Hematology, Departiment of Medicine, Jichi Medical University, Shimotsukeshi, Japan 3Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan 4Division of Stem Cell Therapy, Center for Stem Cell and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan 5ERATO, Japan Science and Technology Agency, Saitama, Japan 6Department of Developmental Biology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan 7University of Tsukuba, Tsukuba, Japan 8Department of Hematology and Oncology, University of Tokyo, Tokyo, Japan 9Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan 10Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan 11Division of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA 12National Research Institute for Child Health and Development, Tokyo, Japan 13Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan 14Showa University Fujigaoka Hospital, Yokohama, Japan 15Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan